GlassScriptPhysician profile
Sally A Booth
NPI 1669452884
$5,593.91
in general payments reported to CMS, 2019-2025
24 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $822 · 2020: $697 · 2021: $387 · 2022: $647 · 2023: $1,148 · 2024: $748 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,782 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,782.12 |
| Education | $258.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,407.25 | 2020-2025 | Ilumya, Odomzo, Blu-U |
| Abbvie INC. | $929.79 | 2021-2025 | Skyrizi |
| Galderma Laboratories, L.P. | $755.91 | 2020-2025 | Nemluvio |
| Biofrontera INC. | $477.27 | 2019 | |
| Janssen Biotech, INC. | $388.94 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $284.24 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $175.65 | 2023 | Sotyktu |
| Merz North America, INC. | $151.69 | 2022-2023 | Xeomin |
| Lilly USA, LLC | $149.85 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $142.73 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $125.01 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $114.83 | 2024-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $102.77 | 2023-2024 | Vtama |
| Kerecis Limited | $78.74 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Journey Medical Corporation | $65.33 | 2020-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $51.06 | 2022-2023 | Opzelura |
| Mayne Pharma Commercial LLC | $33.92 | 2023-2025 | |
| Ucb, INC. | $31.87 | 2025 | Bimzelx |
| Amgen INC. | $28.60 | 2020-2025 | Otezla |
| Janssen Scientific Affairs, LLC | $23.95 | 2021 | |
| Acera Surgical, INC. | $23.22 | 2023 | Restrata Wound Matrix |
| Vyne Pharmaceuticals INC. | $21.67 | 2020 | |
| Leo Pharma INC. | $17.37 | 2021 | |
| Medline Industries LP | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Booth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.